• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    KalVista Pharmaceuticals, Inc. - Common Stock (NQ:KALV)

    16.36 +0.87 (+5.58%)
    Streaming Delayed Price Updated: 3:32 PM EDT, Mar 19, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 823,619
    Open 15.28
    Bid (Size) 16.33 (200)
    Ask (Size) 16.38 (200)
    Prev. Close 15.49
    Today's Range 15.09 - 16.62
    52wk Range 9.235 - 19.00
    Shares Outstanding 34,233,643
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools ↗
    Spyre Therapeutics focuses on antibody therapies for inflammatory bowel disease, advancing a pipeline aimed at gastrointestinal health. 
    Via The Motley Fool
    News headline image
    What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down ↗
    This ophthalmic biopharma firm develops sustained drug delivery therapies for eye diseases, targeting both U.S. and global markets. 
    Via The Motley Fool
    Topics Regulatory Compliance

    Performance

    YTD
    +5.8%
    +5.8%
    1 Month
    +9.1%
    +9.1%
    3 Month
    +10.1%
    +10.1%
    6 Month
    +22.2%
    +22.2%
    1 Year
    +32.2%
    +32.2%

    More News

    Read More
    News headline image
    KalVista Pharmaceuticals to Report Eight Months Fiscal Year 2025 Financial Results and Provide Corporate Update on March 25, 2026
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    VR Adviser Adds Over 1 Million Savara Shares ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    KalVista Pharmaceuticals Presents New Data Highlighting High Patient Satisfaction and Evolving Treatment Trends with EKTERLY® (sebetralstat)
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    KalVista Pharmaceuticals Announces Inclusion of EKTERLY® (sebetralstat) as a First-Line Therapy for Adolescents 12 and Older in International Pediatric HAE Guideline
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    KalVista Pharmaceuticals to Present EKTERLY® (sebetralstat) Data at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    KalVista Pharmaceuticals Stock Rallies After Hours On Strong Genetic Disorder Drug Sales Kickstart ↗
    Via Stocktwits
    Get insights into the top gainers and losers of Thursday's after-hours session. ↗
    Via Chartmill
    News headline image
    KalVista Pharmaceuticals Provides Update on Strong EKTERLY® Launch with Preliminary Fourth Quarter and Full Year 2025 Revenue Results
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    KalVista Pharmaceuticals Announces Approval of EKTERLY® (sebetralstat) in Japan, First and Only Oral On-demand Treatment for Hereditary Angioedema
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    These stocks are moving in today's session ↗
    Via Chartmill
    News headline image
    KalVista Pharmaceuticals Provides Operational Update and Reports Third Quarter Financial Results
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Examining the Future: KalVista Pharma's Earnings Outlook ↗
    Via Benzinga
    News headline image
    KalVista Pharmaceuticals Presents New Data Highlighting Patient Satisfaction with EKTERLY® (sebetralstat) and its Potential in Children Ages 2-11 at the ACAAI 2025 Annual Scientific Meeting
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    KalVista Pharmaceuticals to Host Third Quarter Financial Results Conference Call and Webcast on November 11, 2025
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Ionis Pharmaceuticals (NASDAQ:IONS) Ascends to Six-Year High, Fueled by Breakthrough Pipeline and Robust Sales Outlook
    Via MarketMinute
    News headline image
    KalVista Pharmaceuticals Presents New Data Highlighting the Potential of EKTERLY® (sebetralstat) to Transform On-Demand Hereditary Angioedema Treatment in Europe
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    KalVista Pharmaceuticals Appoints Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire

    Frequently Asked Questions

    Is KalVista Pharmaceuticals, Inc. - Common Stock publicly traded?
    Yes, KalVista Pharmaceuticals, Inc. - Common Stock is publicly traded.
    What exchange does KalVista Pharmaceuticals, Inc. - Common Stock trade on?
    KalVista Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for KalVista Pharmaceuticals, Inc. - Common Stock?
    The ticker symbol for KalVista Pharmaceuticals, Inc. - Common Stock is KALV on the Nasdaq Stock Market
    What is the current price of KalVista Pharmaceuticals, Inc. - Common Stock?
    The current price of KalVista Pharmaceuticals, Inc. - Common Stock is 16.36
    When was KalVista Pharmaceuticals, Inc. - Common Stock last traded?
    The last trade of KalVista Pharmaceuticals, Inc. - Common Stock was at 03/19/26 03:32 PM ET
    What is the market capitalization of KalVista Pharmaceuticals, Inc. - Common Stock?
    The market capitalization of KalVista Pharmaceuticals, Inc. - Common Stock is 559.89M
    How many shares of KalVista Pharmaceuticals, Inc. - Common Stock are outstanding?
    KalVista Pharmaceuticals, Inc. - Common Stock has 560M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.